

PHARMACY BENEFIT PRIOR AUTHORIZATION UPDATES

10/24/2024

Below are upcoming updates to pharmacy benefit medication prior authorization criteria for Community Health Choice's Marketplace plans.

Marketplace Premier Plans

Drug/Class	Effective Date	Overview
Palforzia	11/1/2024	Expanding age to 1 year of age
Ofev	1/1/2025	Updating systemic sclerosis-associated interstitial lung disease (SSc-ILD) criteria based on new guidelines; Adding rituximab and tocilizumab step
Aimovig	11/1/2024	Removing requirement for separate trials of CGRP and botulinum toxin before approving combination
Ajovy	11/1/2024	Removing requirement for separate trials of CGRP and botulinum toxin before approving combination
sorafenib (Nexavar equiv)	11/1/2024	Adding criteria for off-label use for desmoid tumors
Cimzia	11/1/2024	Adding Tyenne (biosimilar to Actemra) as a preferred product option where Actemra is listed as a step option
Orencia	11/1/2024	Adding Tyenne (biosimilar to Actemra) as a preferred product option where Actemra is listed as a step option
Olumiant	11/1/2024	Adding Tyenne (biosimilar to Actemra) as a preferred product option where Actemra is listed as a step option
Kevzara	11/1/2024	Adding Tyenne (biosimilar to Actemra) as a preferred product option where Actemra is listed as a step option

Marketplace Select Plans

Drug/Class	Effective Date	Overview
Palforzia	11/1/2024	Expanding age to 1 year of age
sorafenib (Nexavar equiv)	11/1/2024	Adding criteria for off-label use for desmoid tumors
Cimzia	11/1/2024	Adding Tyenne (biosimilar to Actemra) as a preferred product option where Actemra is listed as a step option
Retevmo	11/1/2024	Adding to formulary with PA